Studying tiny particles in blood to predict treatment response in lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial looks at small particles called extracellular vesicles in your blood to see if they can help predict how well immunotherapy combined with chemotherapy will work for extensive-stage small cell lung cancer. The goal is to find markers that could guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with extensive-stage small cell lung cancer (ES-SCLC).
- Your overall physical condition is good, with an ECOG score of 0 or 1 (meaning you can do all or most daily activities without help).
- You are about to receive immunotherapy combined with chemotherapy for the first time and have never had chemotherapy before.
- You have complete clinical samples (like blood and tissue) and follow-up information available.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of investigational drugs (HS-20093) for people with extensive-stage small cell lung cancer whose disease hasn't progressed after initial treatment. The goal is to see if this approach can keep the cancer from growing.
This study tests a combination of three treatments for extensive-stage small cell lung cancer that has worsened after initial chemotherapy: an experimental pill, focused radiation (SBRT), and an immunotherapy drug. The goal is to see if this triple therapy can help the immune system fight the cancer more effectively.
This study tests a combination of an immunotherapy drug (tislelizumab) plus chemotherapy followed by targeted chest radiation as the first treatment for extensive-stage small cell lung cancer. The goal is to see if adding radiation after chemo-immunotherapy works better than standard treatment alone.
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
This trial tests immunotherapy drugs for extensive stage small cell lung cancer that has progressed after initial (first-line) chemotherapy. You may be eligible if you have finished standard treatment and your cancer has worsened.
This study is testing a new combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus standard chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination can be more effective than current treatments.
Hear when a new Extensive-stage Small Cell Lung Cancer (ES-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.